4basebio PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the commercial launch of its high-capacity single-stranded DNA (ssDNA) product line to accelerate the development of safer and more precise gene therapies by enabling targeted gene editing, advanced cell engineering, and innovative nucleic acid-based medicines.
Built on a proprietary enzyme manufacturing process, this platform provides biopharmaceuticals with highly purified, long-form, end-protected ssDNA templates designed to overcome the significant manufacturing and performance bottlenecks associated with traditional chemical synthesis in CRISPR-based gene editing, enabling large-scale, clinically viable therapies.
With the growth of gene editing and the need for especially complex “knock-in” applications, the demand for longer, purer, and safer DNA templates is increasing exponentially. 4basebio’s ssDNA products enable the generation of constructs up to 10,000 nucleotides with protected ends, ensuring stability, reduced immunogenicity, and a cleaner path to clinical manufacturing.
The technical advantages of this platform will be demonstrated at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting in Boston, Massachusetts. Amine Bouchareb, Director of Molecular Biology and Gene Editing at 4basebio, will present with the following title: “Enzymatic ssDNA platform addresses manufacturing and performance bottlenecks in non-viral CRISPR gene editing.” May 13th at 9 a.m. EDT.
The launch of our ssDNA platform marks a critical milestone in our mission to provide fundamental tools for genomic medicine and personalized treatments.. By replacing traditional chemical synthesis with our scalable cell-free enzymatic approach, our partners can design therapeutics without traditional constraints such as length and sequence complexity. We don’t just provide DNA. We are strengthening the reliability and safety profile necessary for life-changing treatments. ”
Amy Walker, 4basebio CEO
“For too long, researchers have had to choose between the high toxicity of double-stranded DNA and the severe length limitations of chemically synthesized oligonucleotides.” Amin Bouchareb said. “Our enzyme platform eliminates this compromise.”
“At ASGCT, we look forward to presenting data demonstrating how our long-form ssDNA constructs significantly improve homology-directed repair (HDR) gene editing efficiency while maintaining superior cell viability in sensitive primary cell types. This technology provides a bridge between discovery-stage editing and large-scale clinical success.”
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014, as amended by Regulation 11 of the Market Abuse (Amendment) (EU Withdrawal) Regulation 2019/310.
